Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Washington Drug Letter > New Biosimilars Guidance Among CDER’s Planned Docs for 2012

Washington Drug Letter

March 12, 2012 | Vol. 44 No. 11

New Biosimilars Guidance Among CDER’s Planned Docs for 2012

CDER is planning another biosimilars guidance this year that will focus on submitting clinical pharmacology data to show biosimilarity.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives
Sample PDF

Related Articles

EMA Adopts International Guideline on Evaluating Carcinogenic Risk Draft EMA Guideline Sets Biosimilar Groundwork, Clinical Study Comparisons Q&A Guidance Documents Address IND Access, Concerns EMA Details Process for Orphan Drug Designation, Streamlines Fee-Reduction Filings

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.